Patents by Inventor Paul Greenspan

Paul Greenspan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210015915
    Abstract: The present disclosure provides novel compounds of Formula (I) below. Compounds of the disclosure act as STING modulators/agonists. The present disclosure further relates to methods of synthesis of compounds of Formula (I) and methods of using of compounds of Formula (I) for the prophylaxis or treatment of cancer and other STING-related diseases. The compounds have the structure represented by Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 22, 2019
    Publication date: January 21, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Jeffrey CIAVARRI, Dylan Bradley ENGLAND, Kenneth M. GIGSTAD, Alexandra E. GOULD, Paul GREENSPAN, Yongbo HU, Shi-Chung HUANG, Steven Paul LANGSTON, Hirotake MIZUTANI, Zhan SHI, Stepan VYSKOCIL, He XU
  • Patent number: 8440664
    Abstract: This invention provides compounds of formula I: wherein R1, R2, CY, Y1, Y2, X1, X2, and X3 are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: May 14, 2013
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Cardin, Jeffrey Gaulin, Paul Greenspan, Christelle C. Renou, Stepan Vyskocil, Tianlin Xu
  • Publication number: 20120202812
    Abstract: This invention provides compounds of formula I: wherein R1, R2, CY, Y1, Y2, X1, X2, and X3 are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Application
    Filed: April 18, 2012
    Publication date: August 9, 2012
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Cardin, Paul Greenspan, Stepan Vyskocil, Jeffrey Gaulin, Tianlin Xu, Christelle C. Renou
  • Patent number: 8183240
    Abstract: This invention provides compounds of formula I: wherein R1, R2, CY, Y1, Y2, X1, X2, and X3 are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: June 17, 2009
    Date of Patent: May 22, 2012
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Cardin, Paul Greenspan, Stepan Vyskocil, Jeffrey Gaulin, Tianlin Xu, Christelle C. Renou
  • Publication number: 20100075951
    Abstract: This invention provides compounds of formula I: wherein R1, R2, CY, Y1, Y2, X1, X2, and X3 are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Application
    Filed: June 17, 2009
    Publication date: March 25, 2010
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Cardin, Paul Greenspan, Stepan Vyskocil, Jeffrey Gaulin, Tianlin Xu, Christelle C. Renou
  • Publication number: 20080064729
    Abstract: The present invention provides novel phenethylamide compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: September 5, 2007
    Publication date: March 13, 2008
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Alexandra Gould, Paul Greenspan, Tricia Vos
  • Publication number: 20080027060
    Abstract: N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitriles are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof wherein: the symbols are as defined. In particular it has been found that by appropriate choice of groups R, R2, R3, R4, R5, X1, Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.
    Type: Application
    Filed: August 7, 2007
    Publication date: January 31, 2008
    Inventors: Eva Altmann, Claudia Betschart, Keigo Gohda, Miyuki Horiuchi, Rene Lattmann, Martin Missbach, Junichi Sakaki, Michihiro Takai, Naoki Teno, Scott Cowen, Paul Greenspan, Leslie McQuire, Ruben Tommasi, John van Duzer
  • Publication number: 20070149533
    Abstract: The present invention provides novel bicyclic compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: December 7, 2006
    Publication date: June 28, 2007
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Emily Calderwood, Matthew Duffey, Alexandra Gould, Paul Greenspan, Bheemashankar Kulkarni, Matthew LaMarche, Robyn Rowland, Ming Tregay, Tricia Vos
  • Publication number: 20060160803
    Abstract: The present invention provides novel cinnamide compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: January 12, 2006
    Publication date: July 20, 2006
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ruth Adams, Emily Calderwood, Alexandra Gould, Paul Greenspan, Matthew LaMarche, Yuan Tian, Tricia Vos
  • Publication number: 20060035920
    Abstract: Disclosed are novel inhibitors of Chk-1 and methods of using the same for therapy.
    Type: Application
    Filed: May 27, 2005
    Publication date: February 16, 2006
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Robert Boyle, Hassan Imogai, Michael Cherry, Alfred Humphries, Eva Navarro, David Owen, Natalie Dales, Matthew LaMarche, Courtney Cullis, Alexandra Gould, Paul Greenspan